In a landmark update, the NCCN has added two noninvasive tests—ColoSense and Shield—to its official colorectal cancer screening guidelines.
✅ ColoSense, the first FDA-approved stool RNA test, shows 94% sensitivity for colorectal cancer (including 100% for Stage I) and detects nearly half of advanced adenomas.
✅ Shield, a blood-based test detecting ctDNA, offers 83.1% sensitivity for CRC and over 89% specificity—but with lower performance for precancerous lesions.
Both are recommended every 3 years—but only Shield carries a note: it’s best for patients unwilling to screen via other methods.